EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada, Yusuke Tachibana, Atsushi Osoegawa und 6 weitere

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Ryota Nakamura und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Axl Receptor Tyrosine Kinase. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in high-AXL-expressing EGFR-mutated non-small cell lung cancer (NSCLC) cells. Nevertheless, certain residual cells are anticipated to eventually develop acquired resistance to this combination therapy. In this study, we attempted to establish a multidrug combination therapy from the first-line setting to overcome resistance to this combination therapy in high-AXL-expressing EGFR-mutated NSCLC. siRNA screening assay showed that fibroblast growth factor receptor 1 (FGFR1) knockdown induced pronounced inhibition of cell viability in the presence of the osimertinib-ONO-7475 combination, which activates FGFR1 by upregulating FGF2 via the c-Myc pathway. Cell-based assays showed that triple therapy with osimertinib, ONO-7475, and the FGFR inhibitor BGJ398 significantly increased apoptosis by increasing expression of proapoptotic factor Bim and reduced cell viability compared with that observed for the osimertinib-ONO-7475 therapy. Xenograft models showed that triple therapy considerably suppressed tumor regrowth. A novel therapeutic strategy of additional initial FGFR1 inhibition may be highly effective in suppressing the emergence of osimertinib- and ONO-7475-resistant cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsAxl Receptor Tyrosine KinaseCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsProto-Oncogene ProteinsPyrimidinesReceptor Protein-Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 1AnimalsFemaleHumansMiceApoptosisBenzocycloheptenesCell Line, TumorCell SurvivalDrug Resistance, NeoplasmIndolesMice, Inbred BALB CMice, NudeMutationPhenylurea CompoundsPiperazinesProtein Kinase InhibitorsTriazolesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AXLEGFR mutationFGF2FGFR1Non-small-cell lung cancer

Substanzen

AcrylamidesAniline CompoundsAXL protein, humanAxl Receptor Tyrosine KinasebemcentinibBenzocycloheptenesEGFR protein, humanErbB ReceptorsFGFR1 protein, humanIndoles

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address: tayamada@koto.kpu-m.ac.jp.
  • Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
  • Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Research Center of Oncology, Discovery and Research, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Department of Respiratory Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; WPI-Nano Life…

Förderung

  • Japan Society for the Promotion of Science
  • Takeda Science Foundation
  • Ono Pharmaceutical
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Nakamura, R., Yamada, T., Tokuda, S., Morimoto, K., Katayama, Y., Matsui, Y., Hirai, S., Ishida, M., Kawachi, H., Sawada, R., Tachibana, Y., Osoegawa, A., Horinaka, M., Sakai, T., Yasuhiro, T., Kozaki, R., Yano, S., & Takayama, K. (2024). Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217124

Vancouver

Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217124

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Ryota and Yamada, Tadaaki and Tokuda, Shinsaku and Morimoto, Kenji and Katayama, Yuki and Matsui, Yohei and Hirai, Soichi and Ishida, Masaki and Kawachi, Hayato and Sawada, Ryo and Tachibana, Yusuke and Osoegawa, Atsushi and Horinaka, Mano and Sakai, Toshiyuki and Yasuhiro, Tomoko and Kozaki, Ryohei and Yano, Seiji and Takayama, Koichi},
  title = {Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217124}
}
Kostenlos starten →